AI assistant
Sending…
Salarius Pharmaceuticals, Inc. — Director's Dealing 2019
Sep 13, 2019
35494_dirs_2019-09-12_daa7e6fc-61a3-4fae-9078-9780cbfc959d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2019-09-10
Reporting Person: McVicar William K. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-09-10 | Stock Option (right to buy) | $8.0 | A | 3000 | Acquired | 2029-09-10 | Common Stock (3000.0) | Direct |
Footnotes
F1: On July 19, 2019, the Issuer effected a 1-for-25 reverse stock split of its then outstanding common stock, resulting in the reporting person's ownership of 34,385 options.
More from Salarius Pharmaceuticals, Inc.
Regulatory Filings
2026
May 19
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Feb 25
Major Shareholding Notification
2026
Feb 17
Proxy Solicitation & Information Statement
2026
Jan 9
Regulatory Filings
2026
Jan 8
Delisting Announcement
2026
Jan 2
Director's Dealing
2026
Jan 2